SECTION 1: INTRODUCTION 1

• Lecture1.1
  Review, Approval and Reimbursement Process

SECTION 2: OVERVIEW OF THE CANADIAN MARKET ACCESS LANDSCAPE 2

MODULE 1: Key Stakeholders in Market Access

• Lecture2.1
  Chapter 1: Roles and Responsibilities of Payer Stakeholders
• Lecture2.2
  Chapter 2: Value Proposition: Public Payers vs Prescribers

SECTION 2 (contd.): OVERVIEW OF THE CANADIAN MARKET ACCESS LANDSCAPE 3

Module 2: Overview of the Drug Reimbursement Review Process in Canada

• Lecture3.1
  Chapter 1: Review of the Overall Reimbursement Process
• Lecture3.2
  Chapter 2: CDR Review Process
• Lecture3.3
  Chapter 3: pCODR Review Process

SECTION 3: PUBLIC PAYER SUBMISSIONS FOR BRAND DRUG PRODUCTS 3

MODULE 1: CDR Submission Requirements

• Lecture4.1
  Chapter 1: Category 1 CDR Submission Requirements
• Lecture4.2
  Chapter 2: Category 2 CDR Submission Requirements
• Lecture4.3
  Chapter 3: Additional Information

SECTION 3 (contd.): PUBLIC PAYER SUBMISSIONS FOR BRAND DRUG PRODUCTS 2

MODULE 2: pCODR Submission Requirements

• Lecture5.1
  Chapter 1: Post-NOC or Post-NOC/c Submission Requirements
• Lecture5.2
  Chapter 2: Pre-NOC or Pre-NOC/c Submission Requirements

SECTION 3 (contd.): PUBLIC PAYER SUBMISSIONS FOR BRAND DRUG PRODUCTS 5

MODULE 3: Provincial Submission Process

• Lecture6.1
  Chapter 1: Ontario
• Lecture6.2
  Chapter 2: British Columbia
• Lecture6.3
  Chapter 3: Alberta
• Lecture6.4
  Chapter 4: Atlantic Provinces
• Lecture6.5
  Chapter 5: Health Canada’s Non-Insured Health Benefits Drug Plan (NIHB)